SOUTH SAN FRANCISCO, Calif. - Vistagen Therapeutics (VTGN), a clinical-stage biopharmaceutical company with a market ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Roche has entered into an agreement with Evotec to fund the Phase II clinical development of a selective N-methyl-D-aspartate (NMDA) receptor antagonist, EVT 101, for patients with treatment ...

It is the first and only oral NMDA receptor antagonist to be approved for this use, and the first oral therapy with a new mechanism of action in around 60 years, said Axsome. NMDA antagonist ...

In this study, recently published in Alzheimer's & Dementia, the authors investigated NMDA (N-methyl-D-aspartate receptors) receptors due to their importance in synaptic transmission and their ...

The interplay of opiate and NMDA glutamate receptors may contribute to psychosis, cognitive function, alcoholism, and substance dependence. Ketamine and ethanol block the NMDA glutamate receptor.

NMDA receptors, members of the excitatory ionotropic glutamate receptor family, are essential to these processes. They regulate the strength of synaptic connections, playing a critical role in ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

Using a battery of modern neurophysiologic approaches, Suzanne Zukin and collaborators from Albert Einstein College of Medicine in New York delved far into the regulation of these NMDA receptors, ...